Soligenix Inc.'s CEO Christopher Schaber Interviewed by The Life Sciences Report
(firmenpresse) - SAN FRANCISCO, CA -- (Marketwired) -- 04/09/15 -- Orphan diseases associated with inflammation present excellent development opportunities for small biopharmaceutical companies and their investors. Additionally, inflammatory conditions can result from treatment with cancer therapeutics. The crossover between inflammation and oncology, coupled with vaccine programs of high strategic value, have allowed (OTCQB: SNGX) to build a significant pipeline with substantial revenue potential. In this , Dr. Christopher J. Schaber, company President and CEO, outlines development programs targeting pediatric Crohn's disease, GI acute radiation syndrome, a rare lymphoma and the threat of ricin.
Soligenix Inc. has a broad technology base covering inflammation, oncology and biodefense. From a development perspective, how do you prioritize these target areas?
We structure our pipeline to individual development teams, so that all programs are priorities. However, as you would imagine, the development phase and timing to critical data play an important role in program prioritization.
We have two U.S. Food and Drug Administration (FDA) fast-tracked, Phase 3, pivotal trials that are set to begin in 2015, one in pediatric Crohn's disease and the other in cutaneous T-cell lymphoma (CTCL), both orphan indications. In addition, we have a Phase 2 fast-tracked trial in oral mucositis in head-and-neck cancer. We expect data from this trial in mid-2015. Due to their development status, these inflammation and oncology programs are high priorities for 2015...
Investors rely on to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that will help you capitalize on these developing trends.
Soligenix Inc. paid The Life Sciences Report to conduct, produce and distribute the interview. Christopher Schaber had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Christopher Schaber and not of The Life Sciences Report or its officers.
Brandon Fung
Tel: 707-981-8107
Email:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 09.04.2015 - 13:15 Uhr
Sprache: Deutsch
News-ID 384594
Anzahl Zeichen: 0
contact information:
Town:
SAN FRANCISCO, CA
Kategorie:
Alternative
Diese Pressemitteilung wurde bisher 180 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Soligenix Inc.'s CEO Christopher Schaber Interviewed by The Life Sciences Report"
steht unter der journalistisch-redaktionellen Verantwortung von
Streetwise Reports (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
